MA45493A - Inhibiteurs d'entrée de hcmv. - Google Patents

Inhibiteurs d'entrée de hcmv.

Info

Publication number
MA45493A
MA45493A MA045493A MA45493A MA45493A MA 45493 A MA45493 A MA 45493A MA 045493 A MA045493 A MA 045493A MA 45493 A MA45493 A MA 45493A MA 45493 A MA45493 A MA 45493A
Authority
MA
Morocco
Prior art keywords
hcmc
entry inhibitors
inhibitors
entry
hcmc entry
Prior art date
Application number
MA045493A
Other languages
English (en)
Inventor
Barbara Adler
Sampaio Kerstin Laib
Christian Sinzger
Cora Stegmann
Original Assignee
Aicuris Anti Infective Cures Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Publication date
Publication of MA45493A publication Critical patent/MA45493A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering N.A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA045493A 2016-06-27 Inhibiteurs d'entrée de hcmv. MA45493A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16176520 2016-06-27

Publications (1)

Publication Number Publication Date
MA45493A true MA45493A (fr) 2019-05-01

Family

ID=56289338

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045493A MA45493A (fr) 2016-06-27 Inhibiteurs d'entrée de hcmv.

Country Status (6)

Country Link
US (2) US11390661B2 (fr)
EP (1) EP3474887A1 (fr)
AR (1) AR108890A1 (fr)
CA (1) CA3028859A1 (fr)
MA (1) MA45493A (fr)
WO (1) WO2018002081A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI759301B (zh) 2016-05-24 2022-04-01 美商安美基公司 聚乙二醇化卡非佐米化合物
US20220380436A1 (en) * 2019-09-17 2022-12-01 The Board Of Trustees Of The University Of Illinois Engineered receptors for human cytomegalovirus and uses thereof
WO2022013304A1 (fr) 2020-07-14 2022-01-20 Aicuris Gmbh & Co. Kg POLYPEPTIDES PDGFRα EN TANT QUE RÉCEPTEURS LEURRES VIRAUX
JP2024512253A (ja) * 2021-02-22 2024-03-19 ジェネンテック, インコーポレイテッド 宿主細胞の表面とヘルペスウイルスとの相互作用を調節するための方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ATE356869T1 (de) 1990-01-12 2007-04-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1993012227A1 (fr) 1991-12-17 1993-06-24 Genpharm International, Inc. Animaux transgeniques non humains capables de produire des anticorps heterologues
IL128780A0 (en) 1996-09-06 2000-01-31 Univ Pennsylvania An inducible method for production of recombinant adeno-associated viruses utilizing T7 polymerase
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6667173B2 (en) * 2000-12-01 2003-12-23 The Schepens Eye Research Institute Nucleic acids encoding platelet derived growth factor-alpha receptors
WO2003020746A1 (fr) 2001-08-30 2003-03-13 Biorexis Pharmaceutical Corporation Proteines de fusion de transferine modifiees
EP1941867B1 (fr) 2002-06-07 2011-10-12 Dyax Corp. Polypeptide contenant domaine de Kunitz modifié
EP1626988A2 (fr) * 2003-05-16 2006-02-22 Receptor Biologix, Inc. Proteines hybrides a intron et procede d'identification et d'utilisation de celles-ci
CA2543360A1 (fr) 2003-10-24 2005-05-06 Joost A. Kolkman Multimeres et monomeres comprenant des domaines de recepteur de lipoproteines de basse densite de classe a et egf
US20100028995A1 (en) 2004-02-23 2010-02-04 Anaphore, Inc. Tetranectin Trimerizing Polypeptides
CA2560046A1 (fr) * 2004-03-16 2005-09-22 Dnavec Research Inc. Procede d'inhibition de la proliferation d'une tumeur
AU2005287557B2 (en) 2004-09-21 2011-10-13 Biontech Ag Use of microproteins as tryptase inhibitors
US20060234347A1 (en) * 2005-04-13 2006-10-19 Harding Thomas C Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors
PT2100614E (pt) 2005-06-17 2013-12-16 Imclone Llc Antagonistas de receptor para tratamento de cancro ósseo metastático
WO2009021150A2 (fr) 2007-08-08 2009-02-12 California Pacific Medical Center Le récepteur du facteur de croissance dérivés des plaquettes tolère l'infectiosité du cytomégalovirus
EP2231860B1 (fr) 2007-12-19 2011-10-05 Affibody AB Polypeptide dérivé d'une protéine et se liant au pdgf
JP5954990B2 (ja) 2008-11-03 2016-07-20 モレキュラー・パートナーズ・アーゲーMolecular Partners Ag Vegf−aレセプター相互作用を阻害する結合タンパク質
AU2010288542B2 (en) 2009-08-27 2014-05-22 Covagen Ag IL-17 binding compounds and medical uses thereof
WO2011053798A2 (fr) 2009-10-30 2011-05-05 The Administrators Of The Tulane Educational Fund Compositions peptidiques et procédés d'inhibition d'une infection par un virus de l'herpès
ES2441803T3 (es) 2009-12-14 2014-02-06 Scil Proteins Gmbh Un método para identificar proteínas de ubicuitina heteromultímeras modificadas con capacidad para unirse a ligandos
HUE043835T2 (hu) 2010-06-08 2019-09-30 Pieris Pharmaceuticals Gmbh IL-4 receptor-alfát kötõ könny-lipokalin muteinek
RU2014140116A (ru) 2012-04-24 2016-06-10 Тромбодженикс Н.В. Антитела против pdgf-c

Also Published As

Publication number Publication date
US20190161532A1 (en) 2019-05-30
CA3028859A1 (fr) 2018-01-04
EP3474887A1 (fr) 2019-05-01
US11390661B2 (en) 2022-07-19
WO2018002081A1 (fr) 2018-01-04
AR108890A1 (es) 2018-10-10
US20210380664A1 (en) 2021-12-09

Similar Documents

Publication Publication Date Title
MA54543A (fr) Inhibiteurs de kif18a
DK3497103T3 (da) Pyridopyrimdinon-cdk2/4/6-inhibitorer
MA52812A (fr) Inhibiteurs de sarm1
JP1640204S (ja) フェンダー
CU20160125A7 (es) Inhibidores de diacilglicerol aciltransferasa 2
DK3681884T3 (da) Rad51-inhibitorer
DK3571192T3 (da) Jak1-selektive inhibitorer
ES2984389T3 (es) Heterociclos de biarilmetilo
DK3630744T3 (da) Pyrazol-magl-inhibitorer
MA52813A (fr) Inhibiteurs de sarm1
MA49006A (fr) Inhibiteurs d'ip6k
MA52809A (fr) Inhibiteurs de sarm1
MA51611A (fr) Inhibiteurs de pi4kiiibêta
DK3601785T3 (da) Belægning
ES1225190Y (es) Conjunto de ducha
DE102018108987A8 (de) Glättwerkzeug
DK3535461T3 (da) Sprængningsbeskyttelsesvæg
DK3481826T3 (da) Tyrosinkinaseinhibitorer
DK3599479T3 (da) Projektildetektering
DK3710457T3 (da) Immunproteasomhæmmere
MA45493A (fr) Inhibiteurs d'entrée de hcmv.
DK3720840T3 (da) Cathepsinhæmmere
DK3701099T3 (da) Vægsystem
MA54235A (fr) Hydrocyclone
ES1216954Y (es) Ducha